Screening of biomarkers for clinical diagnosis of lymphangiomyomatosis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100050460

Enrollment

Unknown

Registered

2021-08-27

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphangiomyomatosis (LAM)

Interventions

Healthy control group:None

S-LAM group:None

TSC-LAM group:None

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: For patients who meet the diagnostic criteria of LAM, the specific inclusion criteria are as follows: 1. Meet the clinical history and lung CT features of LAM; 2. Have one or more of the following features: (1) Tuberous sclerosis complex (TSC); (2) Renal angiomyolipoma (AML); (3) Serum vascular endothelial growth factor-D (VEGF-D)>=800pg/ml; (4) Chylothorax or chyle ascites; (5) Lymphangioma; (6) LAM cells or LAM cell clusters are found in serous effusion or lymph nodes; (7) Histopathologically confirmed LAM (lung, retroperitoneal, or pelvic tumor).

Exclusion criteria

Exclusion criteria: 1. Patients with other types of malignant tumors; 2. The patient has undergone lung transplantation.

Design outcomes

Primary

Measure	Time frame
Comparison of Differential Expression of Plasma Proteins between Groups;	—

Countries

China

Contacts

Public ContactGu Weili

The First Affiliated Hospital of Guangzhou Medical University

greensgu@sina.com+86 18620923600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026